血液病患者米卡芬净延长给药间期的药代动力学:优化抗真菌预防
这项多中心、开放标签、随机试验比较了成人血液病患者米卡芬净300 mg每周两次与100 mg每日一次预防侵袭性真菌病的药代动力学,并采用蒙特卡洛模拟评估700 mg每周一次方案。结果显示,100 mg每日一次、300 mg每周两次和700 mg每周一次的预测中位AUC0-168h分别为690、596和704 mg·h/L。作者认为300 mg每周两次与100 mg每日一次的暴露量相当,为延长给药方案提供了药代动力学依据,但尚需以硬终点开展临床试验验证。
要点
- 米卡芬净300 mg每周两次与100 mg每日一次的预测暴露量相当。
- 700 mg每周一次方案的预测中位AUC0-168h为704 mg·h/L。
- 延长给药间期的药代动力学依据尚需以硬终点临床试验验证。
核心结论
- 米卡芬净300 mg每周两次与100 mg每日一次的暴露量相当。
- 作者为延长给药方案提供了药代动力学依据,该方案尚需以硬终点开展临床试验验证。
研究设计与样本
- 多中心、开放标签、随机试验,纳入20例有侵袭性真菌病风险的成人血液病患者。
- 患者随机接受米卡芬净300 mg每周两次或100 mg每日一次,持续8天。
- 每日采血,于第4/5天和第8天测定药代动力学曲线;对两种受试方案及700 mg每周一次方案进行蒙特卡洛模拟。
主要发现
- 100 mg每日一次、300 mg每周两次和700 mg每周一次的预测中位AUC0-168h(IQR)分别为690(583-829)、596(485-717)和704(585-833)mg·h/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出延长给药方案尚需以硬终点开展临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extended dosing intervals for micafungin could overcome the need for hospitalization for antifungal prophylaxis. OBJECTIVES: This multicentre, open-label, randomized trial compared the pharmacokinetics of 300 mg of micafungin given twice weekly with 100 mg once daily as antifungal prophylaxis in adult haematology patients at risk of developing invasive fungal disease. Secondary objectives were assessment of adequate exposure with an alternative dosing regimen of micafungin (700 mg once weekly) through Monte Carlo simulations and assessment of safety in this patient population. PATIENTS AND METHODS: Twenty adult patients were randomized to receive either 300 mg of micafungin twice weekly or 100 mg once daily for 8 days. Blood samples were drawn daily and pharmacokinetic curves were determined on days 4/5 and 8. Monte Carlo simulations were performed for both investigated regimens as well as a frequently proposed alternative regimen (700 mg once weekly). RESULTS: The predicted median AUC0-168h (IQR) for a typical patient on the investigated regimens of 100 mg once daily and 300 mg twice weekly and the hypothetical regimen of 700 mg once weekly were 690 (583-829), 596 (485-717) and 704 (585-833) mg·h/L, respectively. CONCLUSIONS: We observed comparable exposure with 300 mg of micafungin twice weekly and 100 mg of micafungin once daily. We provide the pharmacokinetic proof for an extended dosing regimen, which now needs to be tested in a clinical trial with hard endpoints.
引用
- Muilwijk EW, Maertens JA, van der Velden WJFM, et al. Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis. J Antimicrob Chemother. 2018. PMID: 30137340. doi:10.1093/jac/dky324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。